WuXi Biologics (Cayman) Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $24.62 billion
- Book Value:
- Revenue TTM:
- $13.09 billion
- Operating Margin TTM:
- Gross Profit TTM:
- $4.83 billion
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
WuXi Biologics (Cayman) Inc had its IPO on under the ticker symbol WXXWY.
The company operates in the Healthcare sector and Biotechnology industry. WuXi Biologics (Cayman) Inc has a staff strength of 10,593 employees.
Shares of WuXi Biologics (Cayman) Inc opened at $11.42 at the start of the last trading session i.e. 2023-03-21.
The stocks traded within a range of $11.42 - $11.7, and closed at $11.67.
This is a -2.99% slip from the previous day's closing price.
A total volume of 288,787 shares were traded at the close of the day’s session.
In the last one week, shares of WuXi Biologics (Cayman) Inc have slipped by -11.76%.
WuXi Biologics (Cayman) Inc's Key Ratios
WuXi Biologics (Cayman) Inc has a market cap of $24.62 billion, indicating a price to book ratio of 6.0334 and a price to sales ratio of 2.0276.
In the last 12-months WuXi Biologics (Cayman) Inc’s revenue was $13.09 billion with a gross profit of $4.83 billion and an EBITDA of $4.60 billion. The EBITDA ratio measures WuXi Biologics (Cayman) Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, WuXi Biologics (Cayman) Inc’s operating margin was 30.66% while its return on assets stood at 5.51% with a return of equity of 12.3%.
In Q2, WuXi Biologics (Cayman) Inc’s quarterly earnings growth was a positive 38.1% while revenue growth was a positive 63.5%.
WuXi Biologics (Cayman) Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $0.26 per share while it has a forward price to earnings multiple of 30.6748 and a PEG multiple of 0.8141. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into WuXi Biologics (Cayman) Inc’s profitability.
WuXi Biologics (Cayman) Inc stock is trading at a EV to sales ratio of 2.2381 and a EV to EBITDA ratio of 5.9714. Its price to sales ratio in the trailing 12-months stood at 2.0276.
WuXi Biologics (Cayman) Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $47.47 billion
- Total Liabilities
- $9.00 billion
- Operating Cash Flow
- Capital Expenditure
- $1.34 billion
- Dividend Payout Ratio
WuXi Biologics (Cayman) Inc ended 2023 with $47.47 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $47.47 billion while shareholder equity stood at $34.46 billion.
WuXi Biologics (Cayman) Inc ended 2023 with $0 in deferred long-term liabilities, $9.00 billion in other current liabilities, 235000.00 in common stock, $9.69 billion in retained earnings and $1.53 billion in goodwill. Its cash balance stood at $8.14 billion and cash and short-term investments were $9.86 billion. The company’s total short-term debt was $2,473,413,000 while long-term debt stood at $531.90 million.
WuXi Biologics (Cayman) Inc’s total current assets stands at $20.66 billion while long-term investments were $0 and short-term investments were $1.73 billion. Its net receivables were $6.04 billion compared to accounts payable of $995.33 million and inventory worth $2.14 billion.
In 2023, WuXi Biologics (Cayman) Inc's operating cash flow was $-1181393500.00 while its capital expenditure stood at $1.34 billion.
Comparatively, WuXi Biologics (Cayman) Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
WuXi Biologics (Cayman) Inc stock is currently trading at $11.67 per share. It touched a 52-week high of $21.539 and a 52-week low of $21.539. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $15.61 and 200-day moving average was $15.31 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 0% of the company’s stock are held by insiders while 0.7% are held by institutions.
Frequently Asked Questions About WuXi Biologics (Cayman) Inc
Similar Industry Stocks (Biotechnology)
WuXi Biologics (Cayman) Inc. provides end-to-end solutions and services for biologics discovery, development and manufacturing in the People’s Republic of China, North America, Europe, and internationally. The company also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, and biologics clinical and manufacturing services; production and sale of medicals; vaccine CDMO and related business; and material supplier activities. WuXi Biologics (Cayman) Inc. has strategic partnership with ImmuneOncia Therapeutics, Legochem Biosciences Inc, Worg Pharma, OncoC4, and Exelixis Inc. The company was incorporated in 2014 and is headquartered in Wuxi, China.